Abstract | CONTEXT: OBJECTIVE: DESIGN: This was a retrospective cohort study from 2003 to 2007, with up to 6 years follow-up. SETTING: Enrollees were participants in Taiwan National Health Insurance. PATIENTS: INTERVENTION: MAIN OUTCOME MEASURE: RESULTS: There were 25 443, 9642, and 31 900 patients in the alendronate, raloxifene, and calcitonin groups, and the mean age was 74.5 years (SD, 9.6). The incidence of VTE in the alendronate, raloxifene, and calcitonin groups was 11.2, 8.5, and 18.8 per 10 000 person-years. Results from Cox analyses showed that alendronate or raloxifene recipients did not have a higher risk for VTE than calcitonin recipients (adjusted hazard ratio for alendronate, 0.84; 95% confidence interval, 0.47-1.51; adjusted hazard ratio for raloxifene, 0.64; 95% confidence interval, 0.33-1.28). CONCLUSION:
|
Authors | Tzu-Chieh Lin, Cheng-Han Lee, Chyun-Yu Yang, Yea-Huei Kao Yang, Swu-Jane Lin |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 99
Issue 5
Pg. 1599-607
(May 2014)
ISSN: 1945-7197 [Electronic] United States |
PMID | 24606074
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bone Density Conservation Agents
- Raloxifene Hydrochloride
- Calcitonin
- Alendronate
|
Topics |
- Aged
- Aged, 80 and over
- Alendronate
(adverse effects, therapeutic use)
- Bone Density Conservation Agents
(adverse effects, therapeutic use)
- Calcitonin
(adverse effects, therapeutic use)
- Female
- Humans
- Incidence
- Male
- Middle Aged
- Osteoporosis
(drug therapy, epidemiology)
- Osteoporotic Fractures
(epidemiology)
- Raloxifene Hydrochloride
(adverse effects, therapeutic use)
- Retrospective Studies
- Risk
- Taiwan
(epidemiology)
- Venous Thromboembolism
(epidemiology)
|